Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/1120009X.2020.1775424 http://scihub22266oqcxt.onion/10.1080/1120009X.2020.1775424 32530369!7298881!32530369     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Chemother 2021 ; 33 (3): 193-197 Nephropedia Template TP {{tp|p=32530369|t=2021. Lopinavir/ritonavir as a third agent in the antiviral regimen for SARS-CoV-2 infection |pdf=|usr=}}{{32530369}} gab.com Text Lopinavir/ritonavir as a third agent in the antiviral regimen for SARS-CoV-2 infection JO: J Chemother http://www.kidney.de/pget.php?&tw=1&pmid=32530369 #FOAvip Corona Virus Disease (CoVID-19) is an emerging public health problem rapidly spread globally. New treatment options for patients with severe symptoms and ways of reducing transmission in the community are taken into consideration. A retrospective study was conducted in the Department of Infectious Diseases of Alexandroupolis (Greece) including 16 patients with CoVID-19. They were classified into two groups, A and B. Group A received lopinavir/ritonavir as a third agent in the antiviral regimen, while group B did not. Lymphocytes were more significantly increased in patients of group A. Ferritin serum levels were also decreased significantly in these patients. Number of days needed for a first negative result of Real Time- Polymerase Chain Reaction (RT-PCR) was lower for Group A. The present study suggests that lopinavir/ritonavir may reduce the viral carriage in a shorter period of time compared with other antiviral regimens. Further studies are needed in order to evaluate the effectiveness of lopinavir/ritonavir in the treatment of patients with SARS-CoV-2 infection. Twit Text FOAVip Lopinavir/ritonavir as a third agent in the antiviral regimen for SARS-CoV-2 infection ????J Chemother http://www.kidney.de/pget.php?&tw=1&pmid=32530369 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32530369 #FOAvip English Wikipedia <ref>{{Cite pmid|32530369}}</ref> Lopinavir/ritonavir as a third agent in the antiviral regimen for SARS-CoV-2 infection #MMPMID32530369 Panagopoulos P; Petrakis V; Panopoulou M; Trypsianis G; Penlioglou T; Pnevmatikos I; Papazoglou D J Chemother 2021[May]; 33 (3): 193-197 PMID32530369show ga Corona Virus Disease (CoVID-19) is an emerging public health problem rapidly spread globally. New treatment options for patients with severe symptoms and ways of reducing transmission in the community are taken into consideration. A retrospective study was conducted in the Department of Infectious Diseases of Alexandroupolis (Greece) including 16 patients with CoVID-19. They were classified into two groups, A and B. Group A received lopinavir/ritonavir as a third agent in the antiviral regimen, while group B did not. Lymphocytes were more significantly increased in patients of group A. Ferritin serum levels were also decreased significantly in these patients. Number of days needed for a first negative result of Real Time- Polymerase Chain Reaction (RT-PCR) was lower for Group A. The present study suggests that lopinavir/ritonavir may reduce the viral carriage in a shorter period of time compared with other antiviral regimens. Further studies are needed in order to evaluate the effectiveness of lopinavir/ritonavir in the treatment of patients with SARS-CoV-2 infection. |*COVID-19 Drug Treatment[MESH] |Adult[MESH] |Aged[MESH] |Antiviral Agents/*therapeutic use[MESH] |COVID-19/virology[MESH] |Drug Combinations[MESH] |Female[MESH] |Humans[MESH] |Lopinavir/*therapeutic use[MESH] |Male[MESH] |Middle Aged[MESH] |Retrospective Studies[MESH] |Ritonavir/*therapeutic use[MESH]Lopinavir/ritonavir as a third agent in the antiviral regimen for SARS(epmc).pdf DeepDyve Pubget Overpricing